Compare · NBSE vs SCYX
NBSE vs SCYX
Side-by-side comparison of NeuBase Therapeutics Inc. (NBSE) and SCYNEXIS Inc. (SCYX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBSE and SCYX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NBSE is the larger of the two at $44.8M, about 1.1x SCYX ($42.4M).
- SCYX has hit the wire 7 times in the past 4 weeks while NBSE has been quiet.
- Company
- NeuBase Therapeutics Inc.
- SCYNEXIS Inc.
- Price
- $0.38-3.32%
- $4.27-4.26%
- Market cap
- $44.8M
- $42.4M
- 1M return
- -
- +3.64%
- 1Y return
- -
- -24.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 0
NeuBase Therapeutics Inc.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
SCYNEXIS Inc.
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Latest NBSE
- NeuBase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by NeuBase Therapeutics Inc.
- NeuBase Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- SEC Form DEFA14A filed by NeuBase Therapeutics Inc.
- 12 Health Care Stocks Moving In Friday's After-Market Session
- NeuBase Therapeutics Expects Trading In Co's Common Stock Will Be Suspended Upon Opening Of Business On May 13
- On May 2, Nasdaq Notified NeuBase Therapeutics Inc That It Has Not Regained Compliance With Minimum Bid Price Requirement
- NeuBase Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- 12 Health Care Stocks Moving In Friday's After-Market Session
Latest SCYX
- Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.
- Director Tinmouth Brian Philippe was granted 2,875 shares, increasing direct ownership by 31% to 12,125 units (SEC Form 4)
- Director Macdonald Guy was granted 2,875 shares, increasing direct ownership by 29% to 12,625 units (SEC Form 4)
- Director Anido Armando was granted 2,875 shares, increasing direct ownership by 32% to 11,750 units (SEC Form 4)
- Director Hastings David C was granted 2,875 shares, increasing direct ownership by 33% to 11,522 units (SEC Form 4)
- Director Hanham Ann was granted 2,875 shares, increasing direct ownership by 33% to 11,577 units (SEC Form 4)
- SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- SCYNEXIS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- SCYNEXIS Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SCYNEXIS Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events